5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Treatment Type (Chemotherapy, Radiation Therapy, Others) and Geography
Fastest Growing Market:
Global Nasopharyngeal Cancer market is expected to witness a steady CAGR of 2.2% during the forecast period. Certain factors that are driving the market growth include a moderate rise in the burden of the disease and growing awareness towards diagnosis and treatment.
There is a growing awareness of the diagnosis and treatment of nasopharyngeal cancer (NPC). Traditionally the public perception regarding nasopharyngeal cancer was very weak due to lack of government initiatives and low incidence rate of the disease. But, the rise in the number of NPC patients in North America region has changed this scenario. In the United States, nasopharyngeal carcinoma (NPC) is a rare malignancy of the upper digestive tract and has an incidence of less than 1 per 100,000. However, this disease has a well-documented regional and ethnic distribution such that individuals of Southern Chinese and Southeast Asian descent are up to 20-40 times more likely to develop NPC than individuals of European ethnicity. To increase community awareness for ethnicities, which are predisposed to nasopharyngeal cancer, various primary healthcare centers have started awareness campaigns to increase the awareness of NPC. Consequently, greater adoption of NPC diagnosis and treatment is being witnessed, which is driving the growth of the global nasopharyngeal cancer market.
Nasopharyngeal cancer is a disease in which malignant cancer cells form in the tissues of the nasopharynx (the upper part of throat behind the nose). Among many factors, ethnic background along with being exposed to the Epstein-Barr virus can affect the risk of nasopharyngeal cancer.
Report scope can be customized per your requirements. Click here.
Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include a combination of both radiotherapy and chemotherapy techniques. These treatment modalities are still in early clinical phases and will make a commercial appearance late during the end of the forecast period or maybe even after that.
To understand key trends, Download Sample Report
In Asia pacific, nasopharyngeal cancer is one of the most common cancers in the head and neck areas. Men are two to three times more likely to develop it than women. The peak age of incidence is between 50 and 60 years. Nasopharyngeal cancer is generally more common in Southeast Asia. The five countries with the highest incidence of nasopharyngeal cancer in the world were China, Indonesia, Vietnam, India and Malaysia, respectively. The standard incidence of nasopharyngeal cancer in the world was 1.2 per 100,000 (in men 1.7 per 100,000; in women, 0.7 per 100,000).
To understand geography trends, Download Sample Report.
The global Nasopharyngeal Cancermarket is highly competitive and consists of a few major players. Companies like Biocon, Bristol Myers Squibb, Cyclacel Pharmaceuticals, F. Hoffman La-Roche, Merck & Co., Novartis, Pfizer, among others, hold the substantial market share in the Nasopharyngeal Cancermarket.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of the Cancer Disease
4.2.2 Growing Awareness Towards Diagnosis and Treatment
4.3 Market Restraints
4.3.1 High Cost of the Treatment
4.3.2 Side Effects Associated with the Disease
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Treatment Type
5.1.2 Radiation Therapy
5.2.1 North America
184.108.40.206 Rest of Europe
5.2.3 Asia Pacific
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.2.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocon Limited
6.1.2 Bristol Myers Squibb
6.1.3 Cyclacel Pharmaceuticals
6.1.4 F. Hoffman La-Roche
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.7 Pfizer, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments